MISSISSAUGA, Ontario, May 3, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. ARLZ ARZ ("Aralez" or the "Company") today announced the results of the matters voted upon at the Company's 2017 annual and special meeting (the "Meeting") of the shareholders of the Company (the "Shareholders") held earlier today, which included the election of directors, as described below.
The total number of common shares of the Company ("Common Shares") represented by Shareholders present in person or represented by proxy at the Meeting was an aggregate of 51,367,656, representing 78.20% of the Company's issued and outstanding Common Shares as of the record date for the Meeting.
According to proxies received and a vote by ballot, the voting results in respect of each of the following eight director nominees, all of whom previously served as directors of the Company, were as follows:
|
Nominee |
Number of Shares |
Percentage of Votes Cast (approximate) | ||
|
Votes For: |
Votes |
Votes For: |
Votes | |
|
Arthur S. Kirsch (Chairperson) |
22,485,659 |
9,875,061 |
69.48% |
30.52% |
|
Adrian Adams |
28,920,565 |
3,440,155 |
89.37% |
10.63% |
|
Jason M. Aryeh |
26,164,091 |
6,196,629 |
80.85% |
19.15% |
|
Neal F. Fowler |
28,935,289 |
3,425,431 |
89.41% |
10.59% |
|
Rob Harris |
22,469,931 |
9,890,789 |
69.44% |
30.56% |
|
Kenneth B. Lee, Jr. |
28,922,730 |
3,437,990 |
89.38% |
10.62% |
|
Seth A. Rudnick, M.D. |
22,527,866 |
9,832,854 |
69.61% |
30.39% |
|
F. Martin Thrasher |
28,932,500 |
3,428,220 |
89.41% |
10.59% |
Each of the other matters put forward before Shareholders for consideration and approval at the Meeting, as described in the Company's proxy statement dated March 23, 2017, was duly approved by the requisite number of votes, with Shareholders voting in favour of holding future non-binding, advisory say-on-pay votes to approve the Company's approach to the compensation of its named executive officers on an annual basis.
Final voting results of all other matters voted on at the Meeting will be made available on EDGAR at www.sec.gov and SEDAR at www.sedar.com.
About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. ARLZ ARZ is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Mississauga, Ontario, Canada, its U.S. Headquarters is in Princeton, New Jersey and its Ireland Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.
Aralez Pharmaceuticals US Inc. Contact:
Nichol L. Ochsner
Executive Director, Investor Relations & Corporate Communications
732-754-2545
nochsner@aralez.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aralez-announces-voting-results-from-2017-annual-and-special-meeting-of-shareholders-300451090.html
SOURCE Aralez Pharmaceuticals Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
